Bakhtina Varvara I, Veprintsev Dmitry V, Zamay Tatiana N, Demko Irina V, Mironov Gleb G, Berezovski Maxim V, Petrova Marina M, Kichkailo Anna S, Glazyrin Yury E
Department of Hematology, Krasnoyarsk Regional Clinical Hospital, 660022 Krasnoyarsk, Russia.
Laboratory for Digital Controlled Drugs and Theranostics, Federal Research Center "Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science", 660036 Krasnoyarsk, Russia.
Proteomes. 2021 Jan 23;9(1):3. doi: 10.3390/proteomes9010003.
The clinical course of chronic lymphocytic leukemia (CLL) is very ambiguous, showing either an indolent nature of the disease or having latent dangerous progression, which, if diagnosed, will require an urgent therapy. The prognosis of the course of the disease and the estimation of the time of therapy initiation are crucial for the selection of a successful treatment strategy. A reliable estimating index is needed to assign newly diagnosed CLL patients to the prognostic groups. In this work, we evaluated the comparative expressions of proteins in CLL blood cells using a label-free quantification by mass spectrometry and calculated the integrated proteomic indexes for a group of patients who received therapy after the blood sampling over different periods of time. Using a two-factor linear regression analysis based on these data, we propose a new pipeline for evaluating model development for estimation of the moment of therapy initiation for newly diagnosed CLL patients.
慢性淋巴细胞白血病（CLL）的临床病程非常不明确，表现为疾病的惰性或潜在的危险进展，一旦确诊，就需要紧急治疗。疾病进程的预后以及治疗开始时间的评估对于选择成功的治疗策略至关重要。需要一个可靠的评估指标来将新诊断的CLL患者分配到预后组。在这项工作中，我们使用基于质谱的无标记定量法评估了CLL血细胞中蛋白质的相对表达，并计算了一组在不同时间段采血后接受治疗的患者的综合蛋白质组学指标。基于这些数据，通过双因素线性回归分析，我们提出了一种新的流程，用于评估新诊断CLL患者治疗开始时机的模型开发。
